epoprostenol: profile and news

Accredo Health Signs Pharmacy Agreement for Flolan  16 May 2006
2006 - (NewsRx.com) -- Accredo Health Group, Inc., announced an exclusive 5-year agreement as the sole specialty pharmacy for Flolan (epoprostenol sodium), a ... - Therapeutics Daily (subscription) (press release),

Myogen Reports 2006 First Quarter Results  May 8, 2006
...and Myogen entered into an agreement whereby Myogen will be responsible for the marketing and distribution of GSK's Flolan (epoprostenol sodium), a life-saving ... - Genetic Engineering News,

Myogen Reports Results for the Integrated Analysis of ARIES-1 and ...  May 3, 2006
...have entered into a global PAH collaboration in which Myogen has distribution and marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the ... - PharmaLive.com (press release),

Myogen to Announce 2006 First Quarter Results on May 8, 2006  Apr 21, 2006
...have entered into a global PAH partnership in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan (epoprostenol sodium) in the ... - International News Service,

Accredo Health Signs Exclusive Five-Year Specialty Pharmacy ...  Apr 17, 2006
...largest specialty pharmacy operation, today announced an exclusive five-year agreement as the sole specialty pharmacy for Flolan(R) (epoprostenol sodium), a ... - International News Service,